RT Journal Article
SR Electronic
T1 Treatment of metastatic transitional cell carcinoma following renal transplantation
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 61
OP 63
VO 56
IS 1
A1 Wood, David P.
A1 Novick, Andrew C.
A1 Johnson, Douglas E.
A1 Streem, Stevan B.
A1 Steinmuller, Donald
YR 1989
UL http://www.ccjm.org/content/56/1/61.abstract
AB Renal transplantation was performed in a patient with a history of surgical excision for localized transitional cell carcinoma. The graft functioned well; however, metastatic transitional cell carcinoma developed following transplantation. The patient was treated sequentially with CISCA (cisplatin, Cy-toxan [cyclophosphamide], and Adriamycin [doxorubicin hydrochloride]) and M-VAC (methotrexate, vinblastine, Adriamycin, and cisplatin) with no alteration in maintenance immunosuppression. Full-dose chemotherapy was well tolerated, with no impairment of renal function, and a demonstrable reduction in tumor burden was achieved. The patient ultimately died of metastatic disease but enjoyed an excellent quality of life throughout the post-transplant period.